MCQ: Infective Endocarditis | Treatment

Explanation

Correct answer: D. Vancomycin + Ceftriaxone

This child has a congenital heart defect and a clinical presentation strongly suggestive of infective endocarditis. After obtaining the appropriate blood cultures, empirical intravenous antibiotic therapy should be considered, particularly if the child is clinically unwell or has evidence of a complicated infection.

Vancomycin provides coverage against important Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA). Ceftriaxone provides activity against many streptococci and other susceptible organisms that may cause native-valve infective endocarditis. The combination therefore offers broad initial coverage while awaiting blood culture identification and susceptibility results.

Once the causative organism is identified, antibiotic therapy should be narrowed and tailored according to culture results, antimicrobial susceptibility, the site of infection, and the child’s clinical response. Infectious diseases and pediatric cardiology consultation is recommended.

Why the other options are incorrect

A. Ceftriaxone — Incorrect

Ceftriaxone is active against many viridans-group streptococci and other susceptible organisms that can cause infective endocarditis. However, it does not provide reliable coverage against MRSA. Ceftriaxone alone may therefore be inadequate as empirical therapy when resistant staphylococcal infection is a concern.

B. Meropenem — Incorrect

Meropenem is a broad-spectrum carbapenem antibiotic with activity against many Gram-positive and Gram-negative organisms. However, it is not routinely recommended as empirical monotherapy for uncomplicated community-acquired native-valve infective endocarditis. Its broad spectrum also exposes the child to unnecessary antimicrobial pressure when narrower options are suitable.

C. Penicillin G — Incorrect

Penicillin G is an important treatment for susceptible streptococcal infective endocarditis, including selected cases caused by viridans-group streptococci. However, it does not reliably cover S. aureus, particularly MRSA, and is therefore not an adequate broad empirical regimen when the causative organism is unknown.

D. Vancomycin + Ceftriaxone — Correct

This combination provides broad Gram-positive coverage, including MRSA, together with activity against many susceptible streptococci and other organisms. It is used in some pediatric institutional protocols for suspected infective endocarditis without prosthetic material. The regimen should be guided by local antimicrobial susceptibility patterns and infectious diseases expertise.

E. Vancomycin alone — Incorrect

Vancomycin provides important coverage against staphylococci, including MRSA, and is useful when a serious Gram-positive infection is suspected. However, monotherapy may not provide adequate coverage for the full range of organisms responsible for infective endocarditis. Additional coverage may be required depending on the clinical setting and suspected pathogens.

Clinical pearl

In suspected pediatric infective endocarditis, obtain blood cultures before antibiotics whenever the child’s clinical condition permits. Start empirical intravenous therapy when indicated, then de-escalate to targeted treatment once the organism and susceptibility profile are available. The empirical regimen must be individualized according to the clinical setting, local resistance patterns, and the presence of prosthetic material.

Reference

Baltimore RS, Gewitz M, Baddour LM, et al. Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association. Circulation. 2015;132(15):1487–1515. doi:10.1161/CIR.0000000000000298.

You can also practice other high-yield MCQ on infective endocarditis.